EUVIMEDOpdag EUVIMED
Crossref

miR‐135b‐5p/PDE3B Axis Regulates Gemcitabine Resistance in Pancreatic Cancer Through Epithelial‐Mesenchymal Transition

Yuxuan Fu, Liangsheng Chen, Neng Lv, Jia Wang, Shuwei Yu, Qilu Fang, Wenxiu Xin iD

Molecular Carcinogenesis · 2025

DOI: 10.1002/mc.23914 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2025. Written by Yuxuan Fu and 6 co-authors. Institution: Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China. Major MEDLINE topics: MicroRNAs, Deoxycytidine, Epithelial-Mesenchymal Transition, Pancreatic Neoplasms. Cited 2 times so far (Crossref); 41 references. Funded by: This study was supported by the National Natural Science Foundation of China and the Zhejiang Provincial Natural Science Foundation of China..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Gemcitabine‐based chemotherapy is an effective treatment for pancreatic cancer (PC), but gemcitabine resistance frequently compromises the therapeutic efficacy, resulting in clinical chemotherapeutic failure and a poor prognosis for patients. In this study, we investigated the mechanisms of gemcitabine chemoresistance in PC by examining the roles of microRNAs linked to gemcitabine resistance and their downstream signaling pathways. In vitro experiments were performed to alter miR‐135b‐5p levels in PC parental and drug‐resistant cells to probe its function. miR‐135b‐5p targets PDE3B was confirmed by using RNA‐seq technology to screen for gemcitabine‐resistance‐associated mRNAs in PC. A series of rescue experiments were performed after cotransfection, demonstrating that PDE3B could reverse miR‐135b‐5p‐mediated chemoresistance and epithelial‐mesenchymal transition (EMT). These findings indicate that the miR‐135b‐5p/PDE3B axis generates resistance by stimulating the EMT signaling pathway, which provides new insights into gemcitabine chemoresistance in PC.

Subjects

MeSH terms (MEDLINE)

MicroRNAsDeoxycytidineEpithelial-Mesenchymal TransitionPancreatic NeoplasmsDrug Resistance, NeoplasmCyclic Nucleotide Phosphodiesterases, Type 3HumansGemcitabineGene Expression Regulation, NeoplasticCell Line, TumorSignal TransductionAntimetabolites, AntineoplasticCell Proliferation

Author keywords

drug resistancegemcitabinemiRNAmiR‐135b‐5ppancreatic cancer (PC)

Substances

MicroRNAsDeoxycytidineGemcitabineMIRN135 microRNA, humanCyclic Nucleotide Phosphodiesterases, Type 3Antimetabolites, Antineoplastic

Authors and institutions

  • Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
  • Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.

ORCID profiles: Wenxiu Xin

Funding

  • This study was supported by the National Natural Science Foundation of China and the Zhejiang Provincial Natural Science Foundation of China.

Cite

APA

Fu, Y., Chen, L., Lv, N., Wang, J., Yu, S., Fang, Q., & Xin, W. (2025). miR‐135b‐5p/PDE3B Axis Regulates Gemcitabine Resistance in Pancreatic Cancer Through Epithelial‐Mesenchymal Transition. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23914

Vancouver

Fu Y, Chen L, Lv N, Wang J, Yu S, Fang Q, et al. miR‐135b‐5p/PDE3B Axis Regulates Gemcitabine Resistance in Pancreatic Cancer Through Epithelial‐Mesenchymal Transition. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23914

BibTeX
@article{Fu2025,
  author = {Fu, Yuxuan and Chen, Liangsheng and Lv, Neng and Wang, Jia and Yu, Shuwei and Fang, Qilu and Xin, Wenxiu},
  title = {miR‐135b‐5p/PDE3B Axis Regulates Gemcitabine Resistance in Pancreatic Cancer Through Epithelial‐Mesenchymal Transition},
  journal = {Molecular Carcinogenesis},
  year = {2025},
  doi = {10.1002/mc.23914}
}
Start for free →